Compare NEOS S&P 500 High Income ETF (SPYI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NEOS S&P 500 High Income ETF vs GeneDx Holdings Corp — how do they compare? NEOS S&P 500 High Income ETF trades at $54.07 (market cap $12.50B), while GeneDx Holdings Corp trades at $67.74 (market cap $2.02B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 6.2× GeneDx Holdings Corp's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NEOS S&P 500 High Income ETF for 57 Days and GeneDx Holdings Corp for 19 Days on average.
| SPYI | WGS | |
|---|---|---|
Market Cap | $12.50B | $2.02B |
Volume | 3,058,962 | 734,640 |
Sector | Income / Options Overlay | Health |
52-Week High | $54.42 | $167.51 |
52-Week Low | $47.98 | $34.51 |
Typical Hold Time | 57 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPYI trades at $53.995, showing minimal daily movement with a slight 0.03% decline. The technical outlook is bullish based on moving averages, though oscillators remain neutral. Recent news highlights SPYI's role in income-focused portfolios, with coverage discussing both its high distribution yields and potential risks to principal value from covered call strategies.
The outlook for SPYI centers on its income generation appeal amid market volatility, but investors should weigh the trade-off between high yields and potential capital erosion. Key risks include sequence risk in retirement portfolios and the cap on upside during strong bull markets.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
